The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -1.40 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -0.94 — flag raised, worth a closer lookWatch
- Earnings quality 74/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Journey Medical Corp reports it. History and quarterly detail are in the app.
- Qbrexza$25.0M
- Emrosi$14.7M
- Accutane$12.9M
- Foam Franchise Products Amzeeq Zilxi$5.9M
- Other Legacy$2.7M
Leadership changes
From Journey Medical Corp's own filings, the day they're filed.
- Ramsey Alloush · Chief Operating Officer · appointmenteff. 2025-04-01
- Joseph Benesch · Chief Financial Officer · appointmenteff. 2023-01-27
- Michael C. Pearce · appointment
Latest filings
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
- DEF 14A · Annual proxy (pay & governance)2026-04-30
- 8-K · Company announcement2026-04-21
- 10-K · Annual report2026-03-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Journey Medical Corp, every answer cited🔒
- The Intelligence Brief — added when Journey Medical Corp's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.